BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Bruin-weller M, Thaçi D, Smith C, Reich K, Cork M, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, Hultsch T, Chen Z, Pirozzi G, Graham N, Shumel B. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t. Br J Dermatol 2018;178:1083-101. [DOI: 10.1111/bjd.16156] [Cited by in Crossref: 185] [Cited by in F6Publishing: 154] [Article Influence: 46.3] [Reference Citation Analysis]
Number Citing Articles
1 Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol 2021:S0190-9622(21)01119-1. [PMID: 34126094 DOI: 10.1016/j.jaad.2021.06.017] [Reference Citation Analysis]
2 Wu J, Guttman-yassky E. Efficacy of biologics in atopic dermatitis. Expert Opinion on Biological Therapy 2020;20:525-38. [DOI: 10.1080/14712598.2020.1722998] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
3 Thaçi D, L Simpson E, Deleuran M, Kataoka Y, Chen Z, Gadkari A, Eckert L, Akinlade B, Graham NMH, Pirozzi G, Ardeleanu M. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci 2019;94:266-75. [PMID: 31109652 DOI: 10.1016/j.jdermsci.2019.02.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
4 Tauber M, Apoil PA, Richet C, Laurent J, De Bonnecaze G, Mouchon E, Cassagne M, Marguery MC, Hegazy S, Konstantinou MP, Severino M, Uthurriague C, Giordano-Labadie F, Didier A, Paul C. Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice. Br J Dermatol 2019;180:1551-2. [PMID: 30633329 DOI: 10.1111/bjd.17629] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
5 Chello C, Carnicelli G, Sernicola A, Gagliostro N, Paolino G, Di Fraia M, Faina V, Muharremi R, Grieco T. Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature. Int J Dermatol 2020;59:716-21. [PMID: 32311089 DOI: 10.1111/ijd.14891] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Marron SE, Tomas-Aragones L, Moncin-Torres CA, Gomez-Barrera M, Aranibar FJG. Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results. Life (Basel) 2021;11:617. [PMID: 34202315 DOI: 10.3390/life11070617] [Reference Citation Analysis]
7 Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C, Magnolo N, Maari C, Feeney C, Biswas P, Tatulych S, Valdez H, Rojo R. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020;396:255-66. [PMID: 32711801 DOI: 10.1016/S0140-6736(20)30732-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 19] [Article Influence: 24.0] [Reference Citation Analysis]
8 Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019;181:459-73. [PMID: 30851191 DOI: 10.1111/bjd.17869] [Cited by in Crossref: 103] [Cited by in F6Publishing: 94] [Article Influence: 34.3] [Reference Citation Analysis]
9 Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A. Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol 2021;184:857-70. [PMID: 32969489 DOI: 10.1111/bjd.19460] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Nusbaum KB, Fleischer S, Fleischer AB Jr. Efficacy of biologics and oral small molecules for atopic dermatitis: a systematic review and meta-analysis. J Dermatolog Treat 2021;:1-11. [PMID: 34620047 DOI: 10.1080/09546634.2021.1986204] [Reference Citation Analysis]
11 Ruiz-Villaverde R, Armario-Hita JC, Dominguez-Cruz J, Pereyra-Rodriguez JJ. The Safety of Dupilumab in Clinical Practice: 52 Weeks of Experience at 5 Referral Hospitals in Andalusia. Actas Dermosifiliogr (Engl Ed) 2020;111:699-700. [PMID: 32531242 DOI: 10.1016/j.ad.2019.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Kaufman BP, Alexis AF. Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases. Curr Allergy Asthma Rep 2018;18:55. [PMID: 30171358 DOI: 10.1007/s11882-018-0804-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Liberman P, Shifera AS, Berkenstock M. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. Cornea 2020;39:784-6. [PMID: 31985517 DOI: 10.1097/ICO.0000000000002262] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
14 Kato A, Kamata M, Ito M, Uchida H, Nagata M, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Ohnishi T, Tada Y. Higher baseline serum lactate dehydrogenase level is associated with poor effectiveness of dupilumab in the long term in patients with atopic dermatitis. J Dermatol 2020;47:1013-9. [DOI: 10.1111/1346-8138.15464] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
15 Rodrigues MA, Nogueira M, Torres T. Dupilumab for atopic dermatitis: evidence to date. G Ital Dermatol Venereol 2019;154:696-713. [PMID: 31210470 DOI: 10.23736/S0392-0488.19.06417-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
16 Qi HJ, Li LF. New Biologics for the Treatment of Atopic Dermatitis: Analysis of Efficacy, Safety, and Paradoxical Atopic Dermatitis Acceleration. Biomed Res Int 2021;2021:5528372. [PMID: 34195265 DOI: 10.1155/2021/5528372] [Reference Citation Analysis]
17 Bakker DS, Ariens LFM, van Luijk C, van der Schaft J, Thijs JL, Schuttelaar MLA, van Wijk F, Knol EF, Balak DMW, van Dijk MR, de Bruin-Weller MS. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol 2019;180:1248-9. [PMID: 30597515 DOI: 10.1111/bjd.17538] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
18 Kage P, Zarnowski J, Simon JC, Treudler R. Atopic dermatitis and psychosocial comorbidities - What's new? Allergol Select 2020;4:86-96. [PMID: 33195970 DOI: 10.5414/ALX02174E] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Kovalenko P, Davis JD, Li M, Rippley R, Ardeleanu M, Shumel B, Graham NMH, Pirozzi G, Kamal MA, DiCioccio AT. Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data. Clin Pharmacol Drug Dev 2020;9:756-67. [PMID: 32096596 DOI: 10.1002/cpdd.780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Busse WW, Maspero JF, Lu Y, Corren J, Hanania NA, Chipps BE, Katelaris CH, FitzGerald JM, Quirce S, Ford LB, Rice MS, Kamat S, Khan AH, Jagerschmidt A, Harel S, Rowe P, Pirozzi G, Amin N, Ruddy M, Graham NMH, Teper A. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol 2020;125:565-576.e1. [PMID: 32474156 DOI: 10.1016/j.anai.2020.05.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
21 Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy 2020;50:5-14. [PMID: 31505066 DOI: 10.1111/cea.13491] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
22 Fourzali K, Golpanian RS, Yosipovitch G. Dupilumab use in atopic dermatitis and beyond in skin diseases. Immunotherapy 2020;12:1221-35. [PMID: 32892674 DOI: 10.2217/imt-2020-0175] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
23 Leshem YA, Bissonnette R, Paul C, Silverberg JI, Irvine AD, Paller AS, Cork MJ, Guttman-Yassky E. Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement. J Eur Acad Dermatol Venereol 2019;33:807-15. [PMID: 30859656 DOI: 10.1111/jdv.15480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Aszodi N, Thurau S, Seegräber M, Bruin‐weller M, Wollenberg A. Management of dupilumab‐associated conjunctivitis in atopic dermatitis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2019;17:488-91. [DOI: 10.1111/ddg.13809] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
25 Agache I, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, Eiwegger T, Eyerich K, Giménez-Arnau A, Gutermuth J, Guttman-Yassky E, Maurer M, Ogg G, Ong PY, O'Mahony L, Schwarze J, Warner A, Werfel T, Palomares O, Jutel M. EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy 2021;76:988-1009. [PMID: 33538044 DOI: 10.1111/all.14690] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
26 Bakker DS, Nierkens S, Knol EF, Giovannone B, Delemarre EM, van der Schaft J, van Wijk F, de Bruin-weller MS, Drylewicz J, Thijs JL. Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers. Journal of Allergy and Clinical Immunology 2021;147:189-98. [DOI: 10.1016/j.jaci.2020.04.062] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
27 Malipiero G, Heffler E, Pelaia C, Puggioni F, Racca F, Ferri S, Spinello L, Merigo M, Lamacchia D, Cataldo G, Sansonna M, Canonica GW, Paoletti G. Allergy clinics in times of the SARS-CoV-2 pandemic: an integrated model. Clin Transl Allergy 2020;10:23. [PMID: 32566128 DOI: 10.1186/s13601-020-00333-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
28 Schmitt J. After the approval of dupilumab for moderate-to-severe atopic dermatitis: what is next on the research agenda? Br J Dermatol 2018;178:992-3. [PMID: 29785811 DOI: 10.1111/bjd.16505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Siegels D, Heratizadeh A, Abraham S, Binnmyr J, Brockow K, Irvine AD, Halken S, Mortz CG, Flohr C, Schmid-Grendelmeier P, Van der Poel LA, Muraro A, Weidinger S, Werfel T, Schmitt J; European Academy of Allergy, Clinical Immunology Atopic Dermatitis Guideline group. Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis. Allergy 2021;76:1053-76. [PMID: 33074565 DOI: 10.1111/all.14631] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
30 Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M, Hide M, Sher L, Hussain I, Chen Z, Khokhar FA, Beazley B, Ruddy M, Patel N, Graham NMH, Ardeleanu M, Shumel B. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol 2020;21:567-77. [PMID: 32557382 DOI: 10.1007/s40257-020-00527-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
31 Dębińska A. New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression. J Clin Med 2021;10:2506. [PMID: 34198894 DOI: 10.3390/jcm10112506] [Reference Citation Analysis]
32 Boguniewicz M, Beck LA, Sher L, Guttman-Yassky E, Thaçi D, Blauvelt A, Worm M, Corren J, Soong W, Lio P, Rossi AB, Lu Y, Chao J, Eckert L, Gadkari A, Hultsch T, Ruddy M, Mannent LP, Graham NMH, Pirozzi G, Chen Z, Ardeleanu M. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis. J Allergy Clin Immunol Pract 2021;9:1212-1223.e6. [PMID: 33453450 DOI: 10.1016/j.jaip.2020.12.059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Beck LA, Thaçi D, Deleuran M, de Bruin-Weller M, Chen Z, Khokhar FA, Zhang M, Ozturk ZE, Shumel B. Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. J Dermatolog Treat 2021;:1-9. [PMID: 33557637 DOI: 10.1080/09546634.2020.1871463] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Chan CX, Zug KA. Diagnosis and Management of Dermatitis, Including Atopic, Contact, and Hand Eczemas. Med Clin North Am 2021;105:611-26. [PMID: 34059241 DOI: 10.1016/j.mcna.2021.04.003] [Reference Citation Analysis]
35 Badloe FMS, De Vriese S, Coolens K, Schmidt-Weber CB, Ring J, Gutermuth J, Kortekaas Krohn I. IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis. Clin Transl Allergy 2020;10:34. [PMID: 32774842 DOI: 10.1186/s13601-020-00338-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
36 Quint T, Brunner PM, Sinz C, Steiner I, Ristl R, Vigl K, Kimeswenger S, Neubauer K, Pirkhammer D, Zikeli M, Hoetzenecker W, Reider N, Bangert C. Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis. J Clin Med 2020;9:E1241. [PMID: 32344789 DOI: 10.3390/jcm9041241] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
37 Napolitano M, Marasca C, Fabbrocini G, Patruno C. Adult atopic dermatitis: new and emerging therapies. Expert Rev Clin Pharmacol 2018;11:867-78. [PMID: 30073901 DOI: 10.1080/17512433.2018.1507734] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
38 Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, Diepgen T, Fölster-Holst R, Kahle J, Kapp A, Nemat K, Peters E, Schlaeger M, Schmid-Grendelmeier P, Schmitt J, Schwennesen T, Staab D, Traidl-Hoffmann C, Werner R, Wollenberg A, Worm M, Ott H. Update "Systemic treatment of atopic dermatitis" of the S2k-guideline on atopic dermatitis. J Dtsch Dermatol Ges 2021;19:151-68. [PMID: 33491884 DOI: 10.1111/ddg.14371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Brar KK, Nicol NH, Boguniewicz M. Strategies for Successful Management of Severe Atopic Dermatitis. The Journal of Allergy and Clinical Immunology: In Practice 2019;7:1-16. [DOI: 10.1016/j.jaip.2018.10.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
40 Boguniewicz M. Biologics for Atopic Dermatitis. Immunol Allergy Clin North Am 2020;40:593-607. [PMID: 33012322 DOI: 10.1016/j.iac.2020.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
41 Vakharia PP, Silverberg JI. New and emerging therapies for paediatric atopic dermatitis. The Lancet Child & Adolescent Health 2019;3:343-53. [DOI: 10.1016/s2352-4642(19)30030-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
42 Mostafa N, Phan K, Lai B, Smith SD. Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: a systematic review and network meta-analysis. Expert Rev Clin Pharmacol 2021;14:1435-44. [PMID: 34410205 DOI: 10.1080/17512433.2021.1970529] [Reference Citation Analysis]
43 Doan S, Arnould L, Febvay C, Fournié P, Gueudry J, Labalette P, Ouilhon C, Tran T, Vabres B, Barbarot S, Bouaziz J, Du-thanh A, Jachiet M, Seneschal J, Soria A, Staumont-sallé D, Baudouin C, Mortemousque B. Blépharo-conjonctivites sous dupilumab : recommandations du groupe CEDRE. Dermatite atopique, conjonctivites et dupilumab : quelle prise en charge ? Journal Français d'Ophtalmologie 2022. [DOI: 10.1016/j.jfo.2021.12.007] [Reference Citation Analysis]
44 Silverberg JI, Yosipovitch G, Simpson EL, Kim BS, Wu JJ, Eckert L, Guillemin I, Chen Z, Ardeleanu M, Bansal A, Kaur M, Rossi AB, Graham NM, Patel N, Gadkari A. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. Journal of the American Academy of Dermatology 2020;82:1328-36. [DOI: 10.1016/j.jaad.2020.02.060] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]
45 Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z, Kosloski MP, Kamal MA, Delevry D, Chuang CC, O'Malley JT, Bansal A. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol 2022. [PMID: 35567671 DOI: 10.1007/s40257-022-00683-2] [Reference Citation Analysis]
46 Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, Diepgen T, Fölster-Holst R, Kahle J, Kapp A, Nemat K, Peters E, Schlaeger M, Schmid-Grendelmeier P, Schmitt J, Schwennesen T, Staab D, Traidl-Hoffmann C, Werner R, Wollenberg A, Worm M, Ott H. Aktualisierung„ Systemtherapie bei Neurodermitis“ zur S2k-Leitlinie Neurodermitis. J Dtsch Dermatol Ges 2021;19:151-69. [PMID: 33491881 DOI: 10.1111/ddg.14371_g] [Reference Citation Analysis]
47 Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, Suprun M, Estrada Y, Xu H, Peng X, Silverberg JI, Menter A, Krueger JG, Zhang R, Chaudhry U, Swanson B, Graham NMH, Pirozzi G, Yancopoulos GD, D Hamilton JD. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 2019;143:155-72. [PMID: 30194992 DOI: 10.1016/j.jaci.2018.08.022] [Cited by in Crossref: 176] [Cited by in F6Publishing: 151] [Article Influence: 44.0] [Reference Citation Analysis]
48 Chiricozzi A, Maurelli M, Gori N, Argenziano G, De Simone C, Calabrese G, Girolomoni G, Peris K. Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. Journal of the American Academy of Dermatology 2020;83:39-45. [DOI: 10.1016/j.jaad.2020.03.049] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
49 Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol 2020;82:377-88. [PMID: 31374300 DOI: 10.1016/j.jaad.2019.07.074] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 16.0] [Reference Citation Analysis]
50 Newsom M, Bashyam AM, Balogh EA, Feldman SR, Strowd LC. New and Emerging Systemic Treatments for Atopic Dermatitis. Drugs 2020;80:1041-52. [PMID: 32519223 DOI: 10.1007/s40265-020-01335-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
51 Barbieri JS, Bunya VY, Massaro-Giordano M, Margolis DJ. Encounters and medication use for ocular surface disorders among patients treated with dupilumab: A cohort study. JAAD Int 2021;4:1-9. [PMID: 34409381 DOI: 10.1016/j.jdin.2021.03.009] [Reference Citation Analysis]
52 Calabrese G, Gambardella A, Licata G, Di Brizzi EV, Alfano R, Argenziano G. Dupilumab and conjunctivitis: a case series of twenty patients. J Eur Acad Dermatol Venereol 2021;35:e612-4. [PMID: 33657247 DOI: 10.1111/jdv.17210] [Reference Citation Analysis]
53 Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Sirna R, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavò SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Savi E, Stingeni L, Romano A, Argenziano G; On behalf of the Dupilumab Italian National Access Program (Dup-INAP group). Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. Journal of Dermatological Treatment 2021;32:507-13. [DOI: 10.1080/09546634.2019.1682503] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
54 Napolitano M, Maffei M, Patruno C, Leone CA, Di Guida A, Potestio L, Scalvenzi M, Fabbrocini G. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. Dermatol Ther 2021;:e15120. [PMID: 34472171 DOI: 10.1111/dth.15120] [Reference Citation Analysis]
55 Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet 2020;396:345-60. [PMID: 32738956 DOI: 10.1016/S0140-6736(20)31286-1] [Cited by in Crossref: 96] [Cited by in F6Publishing: 48] [Article Influence: 48.0] [Reference Citation Analysis]
56 Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegräber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract 2018;6:1778-1780.e1. [PMID: 29432961 DOI: 10.1016/j.jaip.2018.01.034] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 18.8] [Reference Citation Analysis]
57 Miyano K, Tsunemi Y. Current treatments for atopic dermatitis in Japan. J Dermatol 2021;48:140-51. [PMID: 33377547 DOI: 10.1111/1346-8138.15730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Frampton JE, Blair HA. Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol 2018;19:617-24. [PMID: 30027349 DOI: 10.1007/s40257-018-0370-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
59 Cohen YZ, Zhang X, Xia B, Kosloski MP, Kamal MA, Davis JD, Kanamaluru V, Xu C. Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled Syringe. Clinical Pharm in Drug Dev. [DOI: 10.1002/cpdd.1073] [Reference Citation Analysis]
60 Lee JH, Kim JE, Park GH, Bae JM, Byun JY, Shin MK, Han TY, Hong SP, Jang YH, Kim HO, Na CH, Lew BL, Ahn J, Park CO, Seo YJ, Lee YW, Son SW, Choi EH, Park YL, Roh JY. Consensus Update for Systemic Treatment of Atopic Dermatitis. Ann Dermatol 2021;33:497-514. [PMID: 34858001 DOI: 10.5021/ad.2021.33.6.497] [Reference Citation Analysis]
61 Thibodeaux Q, Smith MP, Ly K, Beck K, Liao W, Bhutani T. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother 2019;15:2129-39. [PMID: 30785362 DOI: 10.1080/21645515.2019.1582403] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
62 Griffiths C, de Bruin-Weller M, Deleuran M, Fargnoli MC, Staumont-Sallé D, Hong CH, Sánchez-Carazo J, Foley P, Seo SJ, Msihid J, Chen Z, Cyr SL, Rossi AB. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. Dermatol Ther (Heidelb) 2021;11:1357-72. [PMID: 34142350 DOI: 10.1007/s13555-021-00558-0] [Reference Citation Analysis]
63 Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S, Kawashima M, Ferrándiz C, Smith CH, Beck LA, Chan KC, Chen Z, Akinlade B, Hultsch T, Staudinger H, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Ardeleanu M. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol 2020;156:131-43. [PMID: 31876900 DOI: 10.1001/jamadermatol.2019.3617] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
64 Andreasen T, Christensen M, Halling A, Egeberg A, Thyssen J. Placebo response in phase 2 and 3 trials of systemic and biological therapies for atopic dermatitis—a systematic review and meta‐analysis. J Eur Acad Dermatol Venereol 2020;34:1143-50. [DOI: 10.1111/jdv.16163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
65 Yosipovitch G, Berger T, Fassett MS. Neuroimmune interactions in chronic itch of atopic dermatitis. J Eur Acad Dermatol Venereol 2020;34:239-50. [PMID: 31566796 DOI: 10.1111/jdv.15973] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
66 Raffi J, Suresh R, Botto N, Murase JE. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart review. Journal of the American Academy of Dermatology 2020;82:132-8. [DOI: 10.1016/j.jaad.2019.09.028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
67 Fabbrocini G, Napolitano M, Megna M, Balato N, Patruno C. Treatment of Atopic Dermatitis with Biologic Drugs. Dermatol Ther (Heidelb) 2018;8:527-38. [PMID: 30182182 DOI: 10.1007/s13555-018-0258-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
68 Li G, Berkenstock M, Soiberman U. Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis. Am J Ophthalmol Case Rep 2020;19:100848. [PMID: 32793843 DOI: 10.1016/j.ajoc.2020.100848] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
69 Bakker DS, van der Wal MM, Heeb LE, Giovannone B, Asamoah M, Delemarre EM, Drylewicz J, Nierkens S, Boyman O, de Bruin-weller MS, Thijs JL, van Wijk F. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis. Journal of Investigative Dermatology 2021;141:1943-1953.e13. [DOI: 10.1016/j.jid.2021.01.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
70 Lázaro-sastre M, García-sánchez A, Gómez-cardeñosa A, Dávila I. Dupilumab in Atopic Dermatitis. Curr Treat Options Allergy 2019;6:211-25. [DOI: 10.1007/s40521-019-00218-x] [Reference Citation Analysis]
71 Ferrucci S, Romagnuolo M, Angileri L, Berti E, Tavecchio S. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports. J Eur Acad Dermatol Venereol 2020;34:e303-4. [PMID: 32330323 DOI: 10.1111/jdv.16527] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
72 Abraham S, Haufe E, Harder I, Heratizadeh A, Kleinheinz A, Wollenberg A, Weisshaar E, Augustin M, Wiemers F, Zink A, Biedermann T, von Kiedrowski R, Hilgers M, Worm M, Pawlak M, Sticherling M, Fell I, Handrick C, Schäkel K, Staubach P, Asmussen A, Schwarz B, Bell M, Neubert K, Effendy I, Bieber T, Homey B, Gerlach B, Tchitcherina E, Stahl M, Schwichtenberg U, Rossbacher J, Buck P, Mempel M, Beissert S, Werfel T, Weidinger S, Schmitt J; TREATgermany study group. Implementation of dupilumab in routine care of atopic eczema: results from the German national registry TREATgermany. Br J Dermatol 2020;183:382-4. [PMID: 32068242 DOI: 10.1111/bjd.18958] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
73 Luger T, Amagai M, Dreno B, Dagnelie MA, Liao W, Kabashima K, Schikowski T, Proksch E, Elias PM, Simon M, Simpson E, Grinich E, Schmuth M. Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents. J Dermatol Sci 2021;102:142-57. [PMID: 34116898 DOI: 10.1016/j.jdermsci.2021.04.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Silverberg JI, Guttman-Yassky E, Gadkari A, Kuznik A, Mallya UG, Mastey V, Zhang H, Chen Z, Chen C, Korotzer A, Sierka D, Fenton MC, Kaur M, Jalbert JJ. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol 2021;126:40-5. [PMID: 32739313 DOI: 10.1016/j.anai.2020.07.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
75 Barnett BP, Afshari NA. Dupilumab-Associated Mucin Deficiency (DAMD). Transl Vis Sci Technol 2020;9:29. [PMID: 32742759 DOI: 10.1167/tvst.9.3.29] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
76 Napolitano M, Mariano M, Cristaudo A, Dastoli S, Di Guida A, De Lucia M, Guerrasio G, Nisticò SP, Passante M, Pigliacelli F, Fabbrocini G, Patruno C. Drug survival analysis of dupilumab and cyclosporin in patients with atopic dermatitis: a multicentre study. J Dermatolog Treat 2022;:1-7. [PMID: 35435125 DOI: 10.1080/09546634.2022.2067818] [Reference Citation Analysis]
77 Tubau C, Puig L. Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Rev Clin Immunol 2021;17:15-25. [PMID: 33275064 DOI: 10.1080/1744666X.2020.1858802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Husein-elahmed H, Steinhoff M. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response. Journal of Dermatological Treatment. [DOI: 10.1080/09546634.2020.1853024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
79 Ariëns LFM, Bakker DS, van der Schaft J, Garritsen FM, Thijs JL, de Bruin-Weller MS. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis 2018;9:159-70. [PMID: 30181845 DOI: 10.1177/2040622318773686] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
80 Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, Seo SJ, Khokhar FA, Vakil J, Xiao J, Marco AR, Levit NA, O'Malley JT, Shabbir A. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol 2022. [PMID: 35503163 DOI: 10.1007/s40257-022-00685-0] [Reference Citation Analysis]
81 Dupuis P, Prokopich CL, Hynes A, Kim H. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunol 2020;16:5. [PMID: 31993069 DOI: 10.1186/s13223-020-0403-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
82 Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, Beck LA, Guttman-Yassky E, Pariser D, Blauvelt A, Weisman J, Lockshin B, Hultsch T, Zhang Q, Kamal MA, Davis JD, Akinlade B, Staudinger H, Hamilton JD, Graham NMH, Pirozzi G, Gadkari A, Eckert L, Stahl N, Yancopoulos GD, Ruddy M, Bansal A. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol 2020;156:44-56. [PMID: 31693077 DOI: 10.1001/jamadermatol.2019.3336] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 44.5] [Reference Citation Analysis]
83 Jo CE, Georgakopoulos JR, Drucker AM, Piguet V, Yeung J. Incidence of Conjunctivitis and Other Ocular Surface Disorders in Patients With Long-Term Dupilumab Use. J Cutan Med Surg 2020;24:527-8. [PMID: 32449620 DOI: 10.1177/1203475420929920] [Reference Citation Analysis]
84 Olesen C, Holm J, Nørreslet L, Serup J, Thomsen S, Agner T. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol 2019;33:1562-8. [DOI: 10.1111/jdv.15609] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
85 Wollenberg A, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q, Shumel B, Khokhar FA, Hultsch T, Rizova E, Rossi AB, Graham NMH, Pirozzi G, Lu Y, Ardeleanu M. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol 2020;182:1120-35. [PMID: 31407311 DOI: 10.1111/bjd.18434] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
86 Ahn J, Choi Y, Simpson EL. Therapeutic New Era for Atopic Dermatitis: Part 1. Biologics. Ann Dermatol 2021;33:1-10. [PMID: 33911806 DOI: 10.5021/ad.2021.33.1.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Silverberg JI, Simpson EL, Ardeleanu M, Thaçi D, Barbarot S, Bagel J, Chen Z, Eckert L, Chao J, Korotzer A, Rizova E, Rossi AB, Lu Y, Graham NMH, Hultsch T, Pirozzi G, Akinlade B. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. Br J Dermatol 2019;181:80-7. [PMID: 30791102 DOI: 10.1111/bjd.17791] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
88 Ariëns LFM, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, Kamsteeg M, Voorberg AN, Oosting AJ, de Ridder I, Sloeserwij A, Haeck I, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. J Am Acad Dermatol 2021;84:1000-9. [PMID: 32946967 DOI: 10.1016/j.jaad.2020.08.127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
89 Napolitano M, Di Guida A, Nocerino M, Fabbrocini G, Patruno C. The emerging role of dupilumab in dermatological indications. Expert Opin Biol Ther 2021;:1-11. [PMID: 33769900 DOI: 10.1080/14712598.2021.1907341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Seegräber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Review of Clinical Pharmacology 2018;11:467-74. [DOI: 10.1080/17512433.2018.1449642] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 13.3] [Reference Citation Analysis]
91 Sears AV, Woolf RT, Gribaleva E, Abdelrahman W, Robbie S, Menon B, Kirkham B, Smith CH, Pink AE. Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated. Br J Dermatol 2021;184:755-7. [PMID: 33107978 DOI: 10.1111/bjd.19631] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
92 Ravn NH, Ahmadzay ZF, Christensen TA, Larsen HHP, Loft N, Rævdal P, Heegaard S, Kolko M, Egeberg A, Silverberg JI, Halling AS, Thyssen JP. Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: A systematic review and meta-analysis. J Am Acad Dermatol 2021;85:453-61. [PMID: 33253849 DOI: 10.1016/j.jaad.2020.11.037] [Reference Citation Analysis]
93 Fukuda K, Ishida W, Kishimoto T, Fukushima A. Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis. Allergology International 2019;68:383-4. [DOI: 10.1016/j.alit.2018.12.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
94 Werfel T. Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018. Current Opinion in Allergy & Clinical Immunology 2018;18:432-7. [DOI: 10.1097/aci.0000000000000477] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
95 Tavecchio S, Angileri L, Pozzo Giuffrida F, Germiniasi F, Marzano AV, Ferrucci S. Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients. J Clin Med 2020;9:E2684. [PMID: 32824992 DOI: 10.3390/jcm9092684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
96 Jonstam K, Swanson BN, Mannent LP, Cardell LO, Tian N, Wang Y, Zhang D, Fan C, Holtappels G, Hamilton JD, Grabher A, Graham NMH, Pirozzi G, Bachert C. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy 2019;74:743-52. [PMID: 30488542 DOI: 10.1111/all.13685] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 18.0] [Reference Citation Analysis]
97 Kamal MA, Kovalenko P, Kosloski MP, Srinivasan K, Zhang Y, Rajadhyaksha M, Lai CH, Kanamaluru V, Xu C, Sun X, Simpson EL, Paller AS, Siegfried EC, Shumel B, Bansal A, Al-Huniti N, Davis JD. The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis. Clin Pharmacol Ther 2021. [PMID: 34270797 DOI: 10.1002/cpt.2366] [Reference Citation Analysis]
98 Havele SA, Khurana MC, Mcmahon P, Murthy AS, Perman MJ, Treat JR. Safety of dupilumab in a 5‐month‐old infant with severe atopic dermatitis. Pediatric Dermatology 2022;39:291-4. [DOI: 10.1111/pde.14980] [Reference Citation Analysis]
99 Agnihotri G, Shi K, Lio PA. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis. Drugs R D 2019;19:311-8. [PMID: 31728936 DOI: 10.1007/s40268-019-00288-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
100 de Bruin-Weller MS, Serra-Baldrich E, Barbarot S, Grond S, Schuster C, Petto H, Capron JP, Raibouaa A, Werfel T. Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb) 2022. [PMID: 35543919 DOI: 10.1007/s13555-022-00734-w] [Reference Citation Analysis]
101 Stölzl D, Weidinger S, Drerup K. A new era has begun: Treatment of atopic dermatitis with biologics. Allergol Select 2021;5:265-73. [PMID: 34532635 DOI: 10.5414/ALX02259E] [Reference Citation Analysis]
102 Matsunaga K, Katoh N, Fujieda S, Izuhara K, Oishi K. Dupilumab: Basic aspects and applications to allergic diseases. Allergol Int. 2020;69:187-196. [PMID: 32007360 DOI: 10.1016/j.alit.2020.01.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
103 Eichenfield LF, Bieber T, Beck LA, Simpson EL, Thaçi D, de Bruin-Weller M, Deleuran M, Silverberg JI, Ferrandiz C, Fölster-Holst R, Chen Z, Graham NMH, Pirozzi G, Akinlade B, Yancopoulos GD, Ardeleanu M. Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. Am J Clin Dermatol 2019;20:443-56. [PMID: 31066001 DOI: 10.1007/s40257-019-00445-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 15.3] [Reference Citation Analysis]
104 Alexander H, Patton T, Jabbar-Lopez ZK, Manca A, Flohr C. Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution? F1000Res 2019;8:F1000 Faculty Rev-132. [PMID: 30774935 DOI: 10.12688/f1000research.17039.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
105 Reszke R, Krajewski P, Szepietowski JC. Emerging Therapeutic Options for Chronic Pruritus. Am J Clin Dermatol 2020;21:601-18. [PMID: 32607945 DOI: 10.1007/s40257-020-00534-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
106 Maudinet A, Law-Koune S, Duretz C, Lasek A, Modiano P, Tran THC. Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis. Ophthalmol Ther 2019;8:485-90. [PMID: 31230264 DOI: 10.1007/s40123-019-0191-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
107 Muzumdar S, Skudalski L, Sharp K, Waldman RA. Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians. Am J Clin Dermatol 2021. [PMID: 34855151 DOI: 10.1007/s40257-021-00646-z] [Reference Citation Analysis]
108 Dhar S, De A, Srinivas SM. Real-World Effectiveness and Safety of Dupilumab for the Treatment of Moderate to Severe Atopic Dermatitis in Indian Patients: A Multi Centric Retrospective Study. Indian J Dermatol 2021;66:297-301. [PMID: 34446954 DOI: 10.4103/ijd.ijd_860_20] [Reference Citation Analysis]
109 Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerregård Øland C, Weidinger S. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol 2021. [PMID: 34698371 DOI: 10.1111/bjd.20832] [Reference Citation Analysis]
110 Tauqeer Z, Jinno SE, Chung CW, Massaro-giordano M, Bunya VY. Clinical Characteristics and Treatment for Dupilumab-Related Ocular Complications in Atopic Dermatitis Patients. OPTH 2022;Volume 16:947-58. [DOI: 10.2147/opth.s336978] [Reference Citation Analysis]
111 Shen E, Xie K, Jwo K, Smith J, Mosaed S. Dupilumab-Induced Follicular Conjunctivitis. Ocul Immunol Inflamm 2019;27:1339-41. [PMID: 30335586 DOI: 10.1080/09273948.2018.1533567] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
112 Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: A systematic review. J Am Acad Dermatol 2021;84:1339-47. [PMID: 33428978 DOI: 10.1016/j.jaad.2021.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
113 Yang N, Chen Z, Zhang X, Shi Y. Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis. BioDrugs 2021;35:401-15. [PMID: 34213742 DOI: 10.1007/s40259-021-00490-x] [Reference Citation Analysis]
114 Thyssen JP, Thomsen SF. Treatment of atopic dermatitis with biologics and Janus kinase inhibitors. Lancet 2021;397:2126-8. [PMID: 34023007 DOI: 10.1016/S0140-6736(21)00717-0] [Reference Citation Analysis]
115 Rodrigues J, Kuruvilla ME, Vanijcharoenkarn K, Patel N, Hom MM, Wallace DV. The spectrum of allergic ocular diseases. Ann Allergy Asthma Immunol 2021;126:240-54. [PMID: 33276116 DOI: 10.1016/j.anai.2020.11.016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Calzavara-Pinton P, Belloni Fortina A, Bonamonte D, Marseglia GL, Miraglia Del Giudice M, Musarra A, Nettis E, Neri I, Patruno C, Stingeni L, Peris K; RADAR Group. Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA), and the Italian Society of Pediatric Dermatology (SIDerP). Ital J Dermatol Venerol 2021;156:184-97. [PMID: 32438781 DOI: 10.23736/S2784-8671.20.06654-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
117 Silverberg JI, Simpson EL, Guttman-Yassky E, Cork MJ, de Bruin-Weller M, Yosipovitch G, Eckert L, Chen Z, Ardeleanu M, Shumel B, Hultsch T, Rossi AB, Hamilton JD, Orengo JM, Ruddy M, Graham NMH, Pirozzi G, Gadkari A. Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials. Dermatitis 2021;32:S81-91. [PMID: 33165005 DOI: 10.1097/DER.0000000000000698] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Barbarot S, Wollenberg A, Silverberg JI, Deleuran M, Pellacani G, Armario-Hita JC, Chen Z, Shumel B, Eckert L, Gadkari A, Lu Y, Rossi AB. Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials. J Dermatolog Treat 2020;:1-12. [PMID: 32347763 DOI: 10.1080/09546634.2020.1750550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Ribero S, Giura MT, Viola R, Ramondetta A, Siliquini N, Cardone P, Tonella L, Quaglino P, Dapavo P, Panzone M, Ortoncelli M, Fierro MT. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real-life Italian tertiary centre experience. J Eur Acad Dermatol Venereol 2020;34:e380-3. [PMID: 31960496 DOI: 10.1111/jdv.16219] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
120 van der Schaft J, Thijs JL, de Bruin-weller MS, Balak DM. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next? Current Opinion in Allergy & Clinical Immunology 2019;19:341-9. [DOI: 10.1097/aci.0000000000000551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
121 Utine CA, Li G, Asbell P, Pflugfelder S, Akpek E. Ocular surface disease associated with dupilumab treatment for atopic diseases. Ocul Surf 2021;19:151-6. [PMID: 32439390 DOI: 10.1016/j.jtos.2020.05.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
122 Corren J, Saini SS, Gagnon R, Moss MH, Sussman G, Jacobs J, Laws E, Chung ES, Constant T, Sun Y, Maloney J, Hamilton JD, Ruddy M, Wang CQ, O'Brien MP. Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial. J Asthma Allergy 2021;14:1045-63. [PMID: 34429614 DOI: 10.2147/JAA.S318892] [Reference Citation Analysis]
123 Wollenberg A, Christen‐zäch S, Taieb A, Paul C, Thyssen J, Bruin‐weller M, Vestergaard C, Seneschal J, Werfel T, Cork M, Kunz B, Fölster‐holst R, Trzeciak M, Darsow U, Szalai Z, Deleuran M, Kobyletzki L, Barbarot S, Heratizadeh A, Gieler U, Hijnen D, Weidinger S, De Raeve L, Svensson Å, Simon D, Stalder J, Ring J; for the European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020;34:2717-44. [DOI: 10.1111/jdv.16892] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
124 Napolitano M, Di Guida A, Fabbrocini G, Patruno C. Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: An Italian single-center experience. Dermatol Ther 2021;:e15059. [PMID: 34241938 DOI: 10.1111/dth.15059] [Reference Citation Analysis]
125 Pereyra-Rodriguez JJ, Alcantara-Luna S, Domínguez-Cruz J, Galán-Gutiérrez M, Ruiz-Villaverde R, Vilar-Palomo S, Armario-Hita JC. Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis. Life (Basel) 2021;11:927. [PMID: 34575076 DOI: 10.3390/life11090927] [Reference Citation Analysis]
126 Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol 2021. [PMID: 34338977 DOI: 10.1007/s12016-021-08880-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
127 van der Schaft J, Thijs JL, Garritsen FM, Balak D, de Bruin-Weller MS. Towards personalized treatment in atopic dermatitis. Expert Opin Biol Ther 2019;19:469-76. [PMID: 30768375 DOI: 10.1080/14712598.2019.1583204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
128 Tanei R. Atopic Dermatitis in Older Adults: A Review of Treatment Options. Drugs Aging 2020;37:149-60. [PMID: 32086792 DOI: 10.1007/s40266-020-00750-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
129 Lee DH, Cohen LM, Yoon MK, Tao JP. Punctal stenosis associated with dupilumab therapy for atopic dermatitis. Journal of Dermatological Treatment. [DOI: 10.1080/09546634.2019.1711010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Castagnoli R, De Filippo M, Votto M, Marseglia A, Montagna L, Marseglia GL, Licari A. An update on biological therapies for pediatric allergic diseases. Minerva Pediatr 2020;72:364-71. [PMID: 32686927 DOI: 10.23736/S0026-4946.20.05993-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
131 Jang DH, Heo SJ, Jung HJ, Park MY, Seo SJ, Ahn J. Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice. J Clin Med 2020;9:E1982. [PMID: 32599878 DOI: 10.3390/jcm9061982] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
132 Li Z, Radin A, Li M, Hamilton JD, Kajiwara M, Davis JD, Takahashi Y, Hasegawa S, Ming JE, DiCioccio AT, Li Y, Kovalenko P, Lu Q, Ortemann-Renon C, Ardeleanu M, Swanson BN. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. Clin Pharmacol Drug Dev 2020;9:742-55. [PMID: 32348036 DOI: 10.1002/cpdd.798] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
133 Barbé J, Poreaux C, Remen T, Schoeffler A, Cloché V, Schmutz JL, Escobar G, Busztejn AC. Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: a bicentric retrospective comparative cohort study. Int J Dermatol 2021. [PMID: 34037253 DOI: 10.1111/ijd.15584] [Reference Citation Analysis]
134 Torres T, Paiva-Lopes MJ, Gonçalo M, Claro C, Oliveira M, Gomes J, Vieira AP, Amoedo P, Alpalhão M, Nogueira M, Santiago F, Henrique M, Amaro C, Esteves T, Alves J, Cerejeira D, Mendes-Bastos P, Pestana M, Ramos L, Rocha J, Carvalho R, Teixeira L, Selores M, Mota A, Filipe P; Portuguese Group of Atopic Dermatitis. Dupilumab for atopic dermatitis: a real-world portuguese multicenter retrospective study. J Dermatolog Treat 2022;:1-12. [PMID: 35083945 DOI: 10.1080/09546634.2022.2035309] [Reference Citation Analysis]
135 Blauvelt A, Simpson EL, Tyring SK, Purcell LA, Shumel B, Petro CD, Akinlade B, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Evans R. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol 2019;80:158-167.e1. [PMID: 30092324 DOI: 10.1016/j.jaad.2018.07.048] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
136 Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, Dellavalle R, Chaiyakunapruk N. Systemic treatments for eczema: a network meta-analysis. Cochrane Database Syst Rev 2020;9:CD013206. [PMID: 32927498 DOI: 10.1002/14651858.CD013206.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
137 Raffi J, Suresh R, Fishman H, Botto N, Murase JE. Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD),. Int J Womens Dermatol 2019;5:308-13. [PMID: 31909149 DOI: 10.1016/j.ijwd.2019.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
138 Matsutani M, Imai Y, Inoue Y, Hosotani Y, Kusakabe M, Natsuaki M, Yamanishi K. Real‐world use of dupilumab for 53 patients with atopic dermatitis in Japan. J Cutan Immunol Allergy 2020;3:35-6. [DOI: 10.1002/cia2.12099] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
139 Uchida H, Kamata M, Mizukawa I, Watanabe A, Agematsu A, Nagata M, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Ohnishi T, Tada Y. Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study. Br J Dermatol 2019;181:1083-5. [PMID: 31127860 DOI: 10.1111/bjd.18163] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
140 Kojanova M, Tanczosova M, Strosova D, Cetkovska P, Fialova J, Dolezal T, Machovcova A, Gkalpakiotis S; BIOREP study group. Dupilumab for the treatment of atopic dermatitis: Real-world data from the Czech Republic BIOREP registry. J Dermatolog Treat 2022;:1-15. [PMID: 35170381 DOI: 10.1080/09546634.2022.2043545] [Reference Citation Analysis]
141 Agache I, Song Y, Posso M, Alonso-Coello P, Rocha C, Solà I, Beltran J, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, Eiwegger T, Eyerich K, Giménez-Arnau A, Gutermuth J, Guttman-Yassky E, Maurer M, Ogg G, Ong PY, O'Mahony L, Schwarze J, Werfel T, Canelo-Aybar C, Palomares O, Jutel M. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. Allergy 2021;76:45-58. [PMID: 32691892 DOI: 10.1111/all.14510] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
142 Lee HH, Patel KR, Rastogi S, Singam V, Vakharia PP, Chopra R, Silverberg JI. Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: A systematic review and meta-analysis. Journal of the American Academy of Dermatology 2020;82:62-71. [DOI: 10.1016/j.jaad.2019.05.102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
143 Bansal A, Simpson EL, Paller AS, Siegfried EC, Blauvelt A, de Bruin-Weller M, Corren J, Sher L, Guttman-Yassky E, Chen Z, Daizadeh N, Kamal MA, Shumel B, Mina-Osorio P, Mannent L, Patel N, Graham NMH, Khokhar FA, Ardeleanu M. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. Am J Clin Dermatol 2021;22:101-15. [PMID: 33481203 DOI: 10.1007/s40257-020-00577-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
144 Paller AS, Beck LA, Blauvelt A, Siegfried EC, Cork MJ, Wollenberg A, Chen Z, Khokhar FA, Vakil J, Zhang A, Bansal A, Cyr SL. Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data. Pediatr Dermatol 2022. [PMID: 35083774 DOI: 10.1111/pde.14909] [Reference Citation Analysis]
145 Schmutz JL. [Risk of conjunctivitis associated with dupilumab (Dupixent®)]. Ann Dermatol Venereol 2018;145:556-8. [PMID: 29941153 DOI: 10.1016/j.annder.2018.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
146 Suga H, Sato S. Novel topical and systemic therapies in atopic dermatitis. Immunological Medicine 2019;42:84-93. [DOI: 10.1080/25785826.2019.1642727] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
147 Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, Cameron MC, Myers DE, Clibborn C, DiBonaventura M. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol 2021;35:1797-810. [PMID: 33991374 DOI: 10.1111/jdv.17351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
148 Wu D, Daniel BS, Lai AJX, Wong N, Lim DKA, Murrell DF, Lim BXH, Mehta JS, Lim CHL. Dupilumab-associated ocular manifestations: A review of clinical presentations and management. Surv Ophthalmol 2022:S0039-6257(22)00030-3. [PMID: 35181280 DOI: 10.1016/j.survophthal.2022.02.002] [Reference Citation Analysis]
149 Paller AS, Wollenberg A, Siegfried E, Thaçi D, Cork MJ, Arkwright PD, Gooderham M, Sun X, O'Malley JT, Khokhar FA, Vakil J, Bansal A, Rosner K, Shumel B, Levit NA. Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. Paediatr Drugs 2021;23:515-27. [PMID: 34462864 DOI: 10.1007/s40272-021-00459-x] [Reference Citation Analysis]
150 Jappe U, Beckert H, Bergmann KC, Gülsen A, Klimek L, Philipp S, Pickert J, Rauber-Ellinghaus MM, Renz H, Taube C, Treudler R, Wagenmann M, Werfel T, Worm M, Zuberbier T. Biologics for atopic diseases: Indication, side effect management, and new developments. Allergol Select 2021;5:1-25. [PMID: 33426426 DOI: 10.5414/ALX02197E] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
151 Blauvelt A, Rosmarin D, Bieber T, Simpson EL, Bagel J, Worm M, Deleuran M, Katoh N, Kawashima M, Shumel B, Chen Z, Rossi AB, Hultsch T, Ardeleanu M. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. Br J Dermatol 2019;181:196-7. [PMID: 30719707 DOI: 10.1111/bjd.17703] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
152 Licari A, Castagnoli R, Marseglia A, Olivero F, Votto M, Ciprandi G, Marseglia GL. Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents. Paediatr Drugs 2020;22:295-310. [PMID: 32157553 DOI: 10.1007/s40272-020-00387-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
153 Salvati L, Cosmi L, Annunziato F. From Emollients to Biologicals: Targeting Atopic Dermatitis. Int J Mol Sci 2021;22:10381. [PMID: 34638722 DOI: 10.3390/ijms221910381] [Reference Citation Analysis]
154 Iwamuro M, Murakami T, Tanaka T, Oka S, Kawano S, Kawahara Y, Okada H. Eosinophilic Gastritis in a Patient Previously Treated with Dupilumab. Case Rep Gastrointest Med 2020;2020:6381670. [PMID: 32566328 DOI: 10.1155/2020/6381670] [Reference Citation Analysis]
155 Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP, Kamal MA, Davis JD, Sun X, Pirozzi G, Graham NMH, Gadkari A, Eckert L, Ruddy M, Bansal A. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol 2021;35:464-75. [PMID: 32893393 DOI: 10.1111/jdv.16928] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
156 Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, Zhang Y, Zhu X, Chen Z, Li M, Ardeleanu M, Teper A, Akinlade B, Gadkari A, Eckert L, Kamal MA, Ruddy M, Graham NMH, Pirozzi G, Stahl N, DiCioccio AT, Bansal A. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol 2020;182:85-96. [PMID: 31595499 DOI: 10.1111/bjd.18476] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 19.0] [Reference Citation Analysis]
157 Ferrucci S, Casazza G, Angileri L, Tavecchio S, Germiniasi F, Berti E, Marzano AV, Genovese G. Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience. J Clin Med 2020;9:E791. [PMID: 32183179 DOI: 10.3390/jcm9030791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
158 Achten R, Bakker D, Ariens L, Lans A, Thijs J, van der Schaft J, de Boer J, Balak D, de Graaf M, van Luijk C, de Bruin-Weller M. Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract 2021;9:1389-1392.e2. [PMID: 33038589 DOI: 10.1016/j.jaip.2020.09.042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
159 Aldredge LM. Atopic Dermatitis With a Focus on Moderate to Severe Disease. The Journal for Nurse Practitioners 2020;16:726-31. [DOI: 10.1016/j.nurpra.2020.08.026] [Reference Citation Analysis]
160 Chis Ster AM, Cornelius V, Cro S. Current approaches to handling rescue medication in asthma and eczema randomized controlled trials are inadequate: a systematic review. J Clin Epidemiol 2020;125:148-57. [PMID: 32504781 DOI: 10.1016/j.jclinepi.2020.05.027] [Reference Citation Analysis]
161 Aszodi N, Thurau S, Seegräber M, de Bruin-Weller M, Wollenberg A. Management der Dupilumab-assoziierten Konjunktivitis beim atopischen Ekzem. J Dtsch Dermatol Ges 2019;17:488-92. [PMID: 31115977 DOI: 10.1111/ddg.13809_g] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
162 Kamata M, Tada Y. A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis. JID Innov 2021;1:100042. [PMID: 34909737 DOI: 10.1016/j.xjidi.2021.100042] [Reference Citation Analysis]
163 Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Arkwright PD, Gooderham M, Beck LA, Boguniewicz M, Sher L, Weisman J, O'malley JT, Patel N, Hardin M, Graham NM, Ruddy M, Sun X, Davis JD, Kamal MA, Khokhar FA, Weinreich DM, Yancopoulos GD, Beazley B, Bansal A, Shumel B. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology 2020;83:1282-93. [DOI: 10.1016/j.jaad.2020.06.054] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 19.0] [Reference Citation Analysis]
164 Bawany F, Northcott CA, Beck LA, Pigeon WR. Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies. J Allergy Clin Immunol Pract 2021;9:1488-500. [PMID: 33321263 DOI: 10.1016/j.jaip.2020.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
165 Ferreira S, Torres T. Conjunctivitis in patients with atopic dermatitis treated with dupilumab. Drugs Context 2020;9:2020-2-3. [PMID: 32426016 DOI: 10.7573/dic.2020-2-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
166 Ahn J, Grinich EE, Choi Y, Guttman-Yassky E, Simpson EL. Emerging Systemic Therapeutic Biologics and Small Molecules for Atopic Dermatitis: How to Decide Which Treatment Is Right for Your Patients. J Allergy Clin Immunol Pract 2021;9:1449-60. [PMID: 33838838 DOI: 10.1016/j.jaip.2021.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Touhouche AT, Cassagne M, Bérard E, Giordano-Labadie F, Didier A, Fournié P, Paul C, Tauber M. Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study. J Eur Acad Dermatol Venereol 2021;35:172-9. [PMID: 32521566 DOI: 10.1111/jdv.16724] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
168 Foerster J, Molęda A. Feasibility Analysis of Interleukin-13 as a Target for a Therapeutic Vaccine. Vaccines (Basel) 2019;7:E20. [PMID: 30759882 DOI: 10.3390/vaccines7010020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
169 Lam M, Zhu JW, Maqbool T, Adam G, Tadrous M, Rochon P, Drucker AM. Inclusion of Older Adults in Randomized Clinical Trials for Systemic Medications for Atopic Dermatitis: A Systematic Review. JAMA Dermatol 2020;156:1240. [DOI: 10.1001/jamadermatol.2020.2940] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
170 Blauvelt A, de Bruin-Weller M, Simpson EL, Chen Z, Zhang A, Shumel B. Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks. Dermatol Ther (Heidelb) 2021. [PMID: 34806137 DOI: 10.1007/s13555-021-00638-1] [Reference Citation Analysis]
171 Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G, Offidani A, Ferrucci SM, Amoruso GF, Rossi M, Stingeni L, Malara G, Grieco T, Foti C, Gattoni M, Loi C, Iannone M, Talamonti M, Stinco G, Rongioletti F, Pigatto PD, Cristaudo A, Nettis E, Corazza M, Guarneri F, Amerio P, Esposito M, Belloni Fortina A, Potenza C, Fabbrocini G; DADE - Dupilumab for Atopic Dermatitis of the Elderly study group. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol 2021;35:958-64. [PMID: 33332697 DOI: 10.1111/jdv.17094] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
172 Descamps V. Quoi de neuf en thérapeutique dermatologique? Annales de Dermatologie et de Vénéréologie 2018;145:VIIS47-55. [DOI: 10.1016/s0151-9638(18)31289-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
173 Lee Y, Kim ME, Nahm DH. Real Clinical Practice Data of Monthly Dupilumab Therapy in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Clinical Efficacy and Predictive Markers for a Favorable Clinical Response. Allergy Asthma Immunol Res 2021;13:733-45. [PMID: 34486258 DOI: 10.4168/aair.2021.13.5.733] [Reference Citation Analysis]
174 Renert-Yuval Y, Del Duca E, Pavel AB, Fang M, Lefferdink R, Wu J, Diaz A, Estrada YD, Canter T, Zhang N, Wagner A, Chamlin S, Krueger JG, Guttman-Yassky E, Paller AS. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol 2021;148:148-63. [PMID: 33453290 DOI: 10.1016/j.jaci.2021.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
175 de Bruin-Weller M, Merola JF, Hong CH, Baldrich ES, Ettler K, Sierka D, Delevry D, Chen Z, Rossi AB. Efficacy of Dupilumab in Atopic Dermatitis: The Patient's Perspective. Dermatol Ther (Heidelb) 2021;11:2123-31. [PMID: 34767181 DOI: 10.1007/s13555-021-00621-w] [Reference Citation Analysis]
176 Beck LA, Silverberg JI, Simpson EL, Yosipovitch G, Eckert L, Guillemin I, Chen Z, Ardeleanu M, Plaum S, Graham N, Ruddy M, Pirozzi G, Gadkari A. Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials. J Eur Acad Dermatol Venereol 2021;35:e130-3. [PMID: 32789996 DOI: 10.1111/jdv.16865] [Reference Citation Analysis]
177 Girolomoni G, de Bruin-Weller M, Aoki V, Kabashima K, Deleuran M, Puig L, Bansal A, Rossi AB. Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chronic Dis 2021;12:20406223211002979. [PMID: 33854747 DOI: 10.1177/20406223211002979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Fölster-Holst R, Torrelo A, Das K, Murrell DF, Patil A, Rahmat Pour Rokni G, Grabbe S, Staubach P, Sohn A, Goldust M. Biological medication in atopic dermatitis. Expert Opin Biol Ther 2022;:1-7. [PMID: 34991429 DOI: 10.1080/14712598.2022.2026920] [Reference Citation Analysis]
179 Blauvelt A, de Bruin-Weller M, Simpson EL, Chen Z, Ardeleanu M, Rossi AB. Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year. Dermatol Ther (Heidelb) 2022. [PMID: 34994968 DOI: 10.1007/s13555-021-00657-y] [Reference Citation Analysis]
180 Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, Nosbaum A, Lasek A, Ferrier le Bouedec MC, Du Thanh A, Raison-Peyron N, Tetart F, Duval-Modeste AB, Misery L, Aubin F, Dompmartin A, Morice C, Droitcourt C, Soria A, Arnault JP, Delaunay J, Mahé E, Richard MA, Schoeffler A, Lacour JP, Begon E, Walter-Lepage A, Dillies AS, Rappelle-Duruy S, Barete S, Bellon N, Bénéton N, Valois A, Barbarot S, Sénéchal J, Staumont-Sallé D; Groupe de Recherche sur l'Eczéma aTopique (GREAT), France. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019;81:143-51. [PMID: 30825533 DOI: 10.1016/j.jaad.2019.02.053] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 22.3] [Reference Citation Analysis]
181 Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, Kamsteeg M, Giovannone B, Drylewicz J, van Amerongen CCA, Delemarre EM, Knol EF, van Wijk F, Nierkens S, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry. Allergy 2020;75:116-26. [PMID: 31593343 DOI: 10.1111/all.14080] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
182 Jia Q, Qiao J, Fang K, Zeng Y. Ocular Adverse Effects in Atopic Dermatitis Patients Treated With Dupilumab: A Bibliometric Analysis. Front Med 2022;9:802036. [DOI: 10.3389/fmed.2022.802036] [Reference Citation Analysis]
183 Jo CE, Georgakopoulos JR, Ladda M, Ighani A, Mufti A, Drucker AM, Piguet V, Yeung J. Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study. J Cutan Med Surg 2020;24:468-73. [DOI: 10.1177/1203475420928907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Nowicki RJ, Trzeciak M, Rudnicka L, Szepietowski J, Kulus M, Kupczyk M, Mastalerz-Migas A, Peregud-Pogorzelski J, Jahnz-Różyk K, Narbutt J, Czarnecka-Operacz M, Czajkowski R, Grubska-Suchanek E, Krasowska D, Kręcisz B, Kowalewski C, Lesiak A, Olszewska M, Samochocki Z, Śpiewak R, Wilkowska A. Biological drugs in the treatment of atopic dermatitis - current recommendations of the Polish Dermatological Society, the Polish Society of Allergology, the Polish Pediatric Society and the Polish Society of Family Medicine. Postepy Dermatol Alergol 2020;37:617-24. [PMID: 33239998 DOI: 10.5114/ada.2020.100496] [Reference Citation Analysis]
185 Thyssen J. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels? Br J Dermatol 2018;178:1220-1220. [DOI: 10.1111/bjd.16330] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
186 Luger T, Dirschka T, Eyerich K, Gollnick H, Gupta G, Lambert J, Micali G, Ochsendorf F, Ständer S, Traidl-Hoffmann C. Developments and challenges in dermatology: an update from the Interactive Derma Academy (IDeA) 2019. J Eur Acad Dermatol Venereol 2020;34 Suppl 7:3-18. [PMID: 33315305 DOI: 10.1111/jdv.17009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
187 Tubau C, Puig L. IL-13 antagonists in the treatment of atopic dermatitis. Immunotherapy 2021;13:327-44. [PMID: 33430628 DOI: 10.2217/imt-2020-0253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Ferrucci S, Romagnuolo M, Maronese CA, Germiniasi F, Tavecchio S, Angileri L, Casazza G, Marzano AV, Genovese G. Skin barrier status during dupilumab treatment in patients with severe atopic dermatitis. Ther Adv Chronic Dis 2021;12:20406223211058332. [PMID: 34900210 DOI: 10.1177/20406223211058332] [Reference Citation Analysis]
189 Thyssen JP, de Bruin-Weller MS, Paller AS, Leshem YA, Vestergaard C, Deleuran M, Drucker AM, Foelster-Holst R, Traidl-Hoffmann C, Eyerich K, Taieb A, Su JC, Bieber T, Cork MJ, Eichenfield LF, Guttman-Yassky E, Wollenberg A. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion. J Eur Acad Dermatol Venereol 2019;33:1224-31. [PMID: 31056788 DOI: 10.1111/jdv.15608] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
190 Nettis E, Patella V, Lombardo C, Detoraki A, Macchia L, Di Leo E, Carbonara M, Canonica GW, Bonzano L. Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis. Allergy 2020;75:2653-61. [PMID: 32424957 DOI: 10.1111/all.14338] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
191 Ruiz‐villaverde R, Dominguez‐cruz J, Armario‐hita JC, Martinez‐pilar L, Alcantara‐luna S, Pereyra‐rodriguez JJ. Fifty‐two week follow‐up safety and effectiveness results of dupilumab treatment of moderate‐to‐severe atopic dermatitis from a retrospective, multicentric series. Dermatologic Therapy 2019. [DOI: 10.1111/dth.12931] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
192 Thyssen J, Halling‐sønderby A, Wu J, Egeberg A. Pain severity and use of analgesic medication in adults with atopic dermatitis: a cross‐sectional study. Br J Dermatol 2020;182:1430-6. [DOI: 10.1111/bjd.18557] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
193 Dhadwal G, Albrecht L, Gniadecki R, Poulin Y, Yeung J, Hong C, Gooderham MJ. Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section IV: Treatment Options for the Management of Atopic Dermatitis. J Cutan Med Surg 2018;22:21S-9S. [DOI: 10.1177/1203475418805721] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]